Monday, October 19, 2026

Is Cannabis use in Turkey Being Politically Instrumentalized?

Ozge Guzel

December 8, 2017

turkey-Istiklal-istanbul-Zumrasha
ANKARA, Turkey (ViaNews) - The history of cannabis use is as old as the history of humanity. In Divan literature during the Ottoman Empire, many poets wrote about intoxicating substances, including cannabis. Also, it was widely used in the shamanic times, before the Islam religion was recognized by the Turks. It was believed that cannabis enabled the shamans to see the future. Cannabis and hashish were made illegal in 1890. In 1925, Turkey and Egypt were the two countries that most vehemently insisted upon cannabis’ inclusion in the Geneva International Convention on Narcotics Control, established by the League of Nations. It is suggested that this was part of a wider move to modernize and align with the West. In 2016, Turkey had legalized strictly-controlled cannabis use for medical purposes in 19 provinces by assigning The Ministry of Food, Agriculture and Livestock to be responsible for the process. The reason for the legalization was because of a drug called Sativex which was formerly prescribed for the cancer patients by the Turkish doctors. The drug was free to obtain within three EU countries but illegal in Turkey. Later on, by following the decision taken by EU countries, the Ministry of Health silently allowed the drug to be sold under the red prescription label. Authorized growers had to annihilate the parts of the cannabis plant after harvest so that it couldn’t be sold to use as psychoactive products. Cannabis, now, can be used in Turkey only for medical or scientific purposes. However, possessing, purchasing or receiving any illegal drug, including cannabis, is punishable by up to two years in prison. Sale and supply of illegal drugs are punishable by prison terms of up to 10 years and unlicensed production or trafficking by a minimum term of 10 years. Cannabis is widely known for its use in healing certain side effects such as eating disorders, nauseation, and depression caused by chemotherapy or anti-cancer drugs. In relation to that, Turkey decided to utilize the active substances found in cannabis and put the spray (Sativex) into medical use. Even though the recreational use of cannabis is still illegal in Turkey, it is allowed to be used with red prescription by doctors. According to the World Drug Report 2008 of the United Nations Office on Drugs and Crime, since the main substance is low in percentage, Turkish cannabis is unfavourable compared to its likes in the world market. But it’s still popular among the young, urban demographic and although explicit consumption may be punished harshly, people usually smoke one way or another and the police often take bribes and let offenders go without further action unless the smoker is also a dealer.
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Sovereign, Local and Open AI: Infrastructure and Applied Intelligence Scale Up While Frontier-Lab Safety Scrutiny Grows
AI is shifting from cloud-rented models toward locally run, owned and open intelligence. ASUS/NVIDIA RTX Spark laptops pair with Nous Research's Hermes and ComfyUI, and Microsoft pushes hybrid local/cloud Windows. Cisco, NVIDIA and Marvell build open high-bandwidth AI infrastructure, and Hesai supplies real-world data for physical AI. In finance and commerce, Intuit, Zeta, Parloa/TELUS Digital and Snipp embed agentic AI into trusted financial and customer workflows, while OpenAI's math breakthroughs, its security disclosures and an executive's departure from its safety role keep safety and governance scrutiny high.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,397 source documents archived
Query this data → isubstrate.com